Switching to bictegravir/emtricitabine/tenofovir alafenamide in people with HIV and prior resistance mutations. Data from the Italian ARCA cohort: the BIC-BARRIER study. B/F/TAF switch: mutations and outcomes
In our cohort of PWH who were switched to B/F/TAF, NRTI-DRMs were common, but B/F/TAF remained effective in maintaining viral suppression despite their presence. However, previous failure to INSTI-based regimens and major INSTI-DRMs were risk factors for VR.
Authors
- Federico Conti (ORCID: https://orcid.org/0000-0002-8057-7488)
- Anna Rita Volpe (ORCID: https://orcid.org/0000-0002-1217-6412)
- Laura Albini
- William Gennari (ORCID: https://orcid.org/0000-0002-8823-8173)
- Laura Pezzati (ORCID: https://orcid.org/0000-0002-7306-342X)
- D. Corsini
- Gabriele Forcina
- Zazzi Maurizio
- Barbara Rossetti
- Stefano Rusconi
- Emanuele Pontali
- Adrian Shallvari
- Ilaria Vicenti
- Bianca Bruzzone
- Annalisa Saracino
- Cristina Mussini
- Alessandro Cozzi-Lepri
Institutions
- University of Siena (IT)
- University of Modena and Reggio Emilia (IT)
- Genesis HealthCare (US)
- Ente Ospedaliero Ospedali Galliera (IT)
- Azienda Unita' Sanitaria Locale Di Modena (IT)
- Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari (IT)
- Azienda Ospedaliero-Universitaria di Modena (IT)
- Alessandro Manzoni Hospital (IT)
- Gilead Sciences (Italy) (IT)
- Centre for Global Health Research (CA)
- Ospedale Misericordia - Grosseto (IT)
- Ospedale Policlinico San Martino (IT)
- Azienda Ospedaliera Ospedale Civile di Legnano (IT)
- University College London (GB)
Publication Details
- Journal
- Journal of Antimicrobial Chemotherapy
- Published
- 2026-01-20
- DOI
- https://doi.org/10.1093/jac/dkag035
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00